Theriva Biologics, Inc. (SYN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Theriva Biologics, Inc. on September 9, 2024, reporting events that occurred on September 6, 2024. The Company is incorporated in Nevada and its common stock trades on the NYSE American under the symbol "SYN".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on a capital structure event involving the conversion of preferred stock.
Material Changes
On September 6, 2024, the Company received and processed a notice of conversion for its Series C and Series D Convertible Preferred Stock:
- Series C Conversion: 4,138 shares converted into 1,086 shares of common stock at a price of $30.50 per share.
- Series D Conversion: 100,000 shares converted into 26,230 shares of common stock at a price of $30.50 per share.
- Total Issuance: An aggregate of 27,316 shares of common stock were issued.
- Outstanding Balance: Following this transaction, there are no shares of Series C or Series D Convertible Preferred Stock outstanding.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies beyond the specific conversion event described in Item 8.01.
Investor Verification Checklist
- Verify the updated total share count of common stock outstanding following the issuance of 27,316 new shares.
- Confirm the elimination of Series C and Series D Convertible Preferred Stock from the Company's capital structure.
- Review the Company's most recent 10-Q or 10-K for financial performance data, as this 8-K does not contain financial statements.